A case of dasatinib-induced focal segmental glomerulosclerosis in a patient with Philadelphia chromosome positive chronic myeloid leukemia
Nephrologie et Therapeutique, cilt.17, sa.1, ss.53-56, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 17 Sayı: 1
- Basım Tarihi: 2021
- Doi Numarası: 10.1016/j.nephro.2020.09.007
- Dergi Adı: Nephrologie et Therapeutique
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, EMBASE, MEDLINE
- Sayfa Sayıları: ss.53-56
- Anahtar Kelimeler: Dasatinib, Focal and segmental glomerulosclerosis, Nephrotic syndrome, Proteinuria
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Focal segmental glomerulosclerosis is a common glomerular histological lesion, which is usually characterised by non-nephrotic range proteinuria or nephrotic syndrome. It may be idiopathic or occurs secondarily to drugs, diabetes, obesity or HIV nephropathy and other infections. Dasatinib, a tyrosine kinase inhibitor that has been used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia, has a few renal adverse effects. Exceptional cases with non-nephrotic range proteinuria have been reported in relation with dasatinib. In this case, we report a patient with symptoms of nephrotic syndrome and nephrotic range proteinuria, who was diagnosed as focal segmental glomerulosclerosis by kidney biopsy after treated with dasatinib.